A Phase II Multicenter, Open Label Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics and PK/PD Profile of Multiple Subcutaneous Injection of KN057 in Male Patients with Severe Hemophilia a or Moderate-to-Severe Hemophilia B with or Without Inhibitors
Latest Information Update: 30 Dec 2024
Price :
$35 *
At a glance
- Drugs KN 057 (Primary)
- Indications Haemophilia A; Haemophilia B
- Focus Adverse reactions
- Sponsors Alphamab Oncology
- 30 Dec 2024 New trial record